HUP0001138A2 - Benzodioxán vagy benzoxazin-gyűrűt tartalmazó aminosavak, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents
Benzodioxán vagy benzoxazin-gyűrűt tartalmazó aminosavak, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukraInfo
- Publication number
- HUP0001138A2 HUP0001138A2 HU0001138A HUP0001138A HUP0001138A2 HU P0001138 A2 HUP0001138 A2 HU P0001138A2 HU 0001138 A HU0001138 A HU 0001138A HU P0001138 A HUP0001138 A HU P0001138A HU P0001138 A2 HUP0001138 A2 HU P0001138A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- acyl
- alkyl
- hydrogen atom
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- -1 bicyclic aromatic amino acids Chemical class 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya (I) általános képletű biciklusos, aromásaminosavak, ahol R1 jelentése hidrogénatom, alkil- vagy benzilcsoport;R2 jelentése R10, CO-R10, COOR6, COOR10, SO2R6 vagy SO2R10; R3jelentése hidrogén- vagy halogénatom, OA, NHR10, N(R10)2, NH-acil-, -O-acil-, ciano-, nitrocsoport, OR10, SR10, R2 vagy CONHR10; R4jelentése hidrogénatom, =O, =S, alkil- vagy acilcsoport; R5 jelentéseamino-, H2N-C(=NH) vagy H2N-(C=NH)-NH- csoport, ahol a primeraminocsoportok szokásos aminovédő-csoporttal lehetnek ellátva, vagyegyszer, kétszer vagy háromszor R10, CO-R10, COOR10 vagy SO2R10csoporttal lehetnek szubsztituálva; vagy R6; R7 és R8 egymástólfüggetlenül hiányzik vagy hidrogénatomot jelent; R7 és R8 együttkötést is képezhetnek; X, Y egymástól függetlenül =N-, -N-, O, S, -CH2- vagy =C- csoportot jelent, azzal a megkötéssel, hogy X és Y kétdefiníciója közül legalább az egyik =N-, -N-, O vagy S jelentésű; W, Zjelentése egymástól függetlenül hiányzik vagy oxigén-, kénatom, NR1,C(=O), CONH, NHCO, C(=S)NH, NHC(=S), C(=S), SO2NH, NHSO2 vagy CA=CA';R11 jelentése hidrogénatom vagy 1-6 szénatomos alkilcsoport; Haljelentése fluor-, klór-, bróm- vagy jódatom; és m, n egymástólfüggetlenül lehet 0, 1, 2, 3 vagy 4, és fiziológiailag elfogadhatósói, valamint eljárás előállításukra. A találmány további tárgya afenti vegyületeket tartalmazó gyógyszerkészítmények, amelyek integrininhibitor hatásuk révén főleg keringési betegségek, trombózis,infarktus, koszorúér szívbetegség, érelmeszesedés, csontritkulás éstumorbetegségek ellen hatásosak. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19705450A DE19705450A1 (de) | 1997-02-13 | 1997-02-13 | Bicyclische aromatische Aminosäuren |
| PCT/EP1998/000636 WO1998035949A1 (de) | 1997-02-13 | 1998-02-06 | Bicyclische aromatische aminosäuren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001138A2 true HUP0001138A2 (hu) | 2001-05-28 |
| HUP0001138A3 HUP0001138A3 (en) | 2002-10-28 |
Family
ID=7820093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001138A HUP0001138A3 (en) | 1997-02-13 | 1998-02-06 | Amino acids containing benzodioxane or benzoxazine, pharmaceutical compositions thereof and process for producing the same |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0964856B1 (hu) |
| JP (1) | JP4327257B2 (hu) |
| KR (1) | KR20000071030A (hu) |
| CN (1) | CN1085205C (hu) |
| AR (1) | AR010894A1 (hu) |
| AT (1) | ATE225776T1 (hu) |
| AU (1) | AU735313B2 (hu) |
| BR (1) | BR9807345A (hu) |
| CA (1) | CA2280727C (hu) |
| CY (1) | CY2341B1 (hu) |
| CZ (1) | CZ297366B6 (hu) |
| DE (2) | DE19705450A1 (hu) |
| DK (1) | DK0964856T3 (hu) |
| ES (1) | ES2183332T3 (hu) |
| HU (1) | HUP0001138A3 (hu) |
| ID (1) | ID22533A (hu) |
| NO (1) | NO313289B1 (hu) |
| PL (1) | PL335101A1 (hu) |
| PT (1) | PT964856E (hu) |
| RU (1) | RU2187506C2 (hu) |
| SI (1) | SI0964856T1 (hu) |
| SK (1) | SK284646B6 (hu) |
| TR (1) | TR199901962T2 (hu) |
| WO (1) | WO1998035949A1 (hu) |
| ZA (1) | ZA981178B (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040063790A1 (en) * | 1996-05-31 | 2004-04-01 | The Scripps Research Institute | Methods for inhibition of angiogenesis |
| CN1140511C (zh) | 1998-04-09 | 2004-03-03 | 明治制果株式会社 | 作为整合素αvβ3拮抗剂的氨基哌啶衍生物 |
| BR0009739A (pt) | 1999-04-13 | 2002-04-09 | Basf Ag | Composto, medicamento, preparação farmacêutica, e, usos de um elemento estrutural, de um composto e de uma preparação farmacêutica |
| WO2001010844A1 (en) | 1999-08-05 | 2001-02-15 | Meiji Seika Kaisha, Ltd. | φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM |
| JP2003519119A (ja) * | 1999-12-24 | 2003-06-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | （ヘテロ）ビシクリルメタンスルホニルアミノ置換ヒドロキサム酸誘導体 |
| WO2001055104A1 (fr) * | 2000-01-25 | 2001-08-02 | Kaneka Corporation | Procede de preparation d'acides azetidine-2-carboxyliques a substitution n optiquement actifs |
| KR20030061390A (ko) * | 2000-11-01 | 2003-07-18 | 메르크 파텐트 게엠베하 | 안구 질환 치료용 조성물 및 방법 |
| US7514098B2 (en) | 2001-05-30 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| MXPA04000839A (es) | 2001-08-01 | 2004-05-14 | Merck Patent Gesellscahft Mit | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. |
| CN1658894A (zh) * | 2002-02-14 | 2005-08-24 | 默克专利股份有限公司 | 用于治疗眼病的方法和组合物 |
| DE10305784A1 (de) * | 2003-02-12 | 2004-08-26 | Merck Patent Gmbh | Verfahren zur Herstellug bicyclischer aromatischer Aminosäuren sowie deren Zwischenprodukte |
| DE10337863A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Verwendung von Chromen-4-on-Derivaten |
| EP1765362B1 (en) * | 2004-06-04 | 2012-03-28 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| RU2518073C2 (ru) * | 2008-12-26 | 2014-06-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Новое бициклическое гетероциклическое соединение |
| WO2011024987A1 (ja) * | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
| TW201350475A (zh) | 2012-03-06 | 2013-12-16 | Boehringer Ingelheim Int | 用於組合療法之白三烯素生成之苯并二噁烷抑制劑 |
| JP6256467B2 (ja) | 2012-07-17 | 2018-01-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成を阻害するピラゾール誘導体 |
| JP2016523982A (ja) | 2013-07-15 | 2016-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成の阻害剤 |
| EP3022193B1 (en) | 2013-07-15 | 2017-04-26 | Boehringer Ingelheim International GmbH | Inhibitors of leukotriene production |
| US10328082B2 (en) | 2014-05-30 | 2019-06-25 | Pfizer Inc. | Methods of use and combinations |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU675689B2 (en) * | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0760658B1 (en) * | 1994-05-27 | 2002-11-13 | Merck & Co. Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
| DE19548709A1 (de) * | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
| DE19654483A1 (de) * | 1996-06-28 | 1998-01-02 | Merck Patent Gmbh | Phenylalanin-Derivate |
| KR20000022190A (ko) * | 1996-06-28 | 2000-04-25 | 플레믹 크리스티안 | 인테그린 저해제로서의 페닐알라닌 유도체 |
-
1997
- 1997-02-13 DE DE19705450A patent/DE19705450A1/de not_active Withdrawn
-
1998
- 1998-02-06 DK DK98908063T patent/DK0964856T3/da active
- 1998-02-06 BR BR9807345A patent/BR9807345A/pt not_active Application Discontinuation
- 1998-02-06 SI SI9830304T patent/SI0964856T1/xx unknown
- 1998-02-06 CA CA002280727A patent/CA2280727C/en not_active Expired - Fee Related
- 1998-02-06 PL PL98335101A patent/PL335101A1/xx unknown
- 1998-02-06 HU HU0001138A patent/HUP0001138A3/hu unknown
- 1998-02-06 PT PT98908063T patent/PT964856E/pt unknown
- 1998-02-06 DE DE59805895T patent/DE59805895D1/de not_active Expired - Lifetime
- 1998-02-06 ES ES98908063T patent/ES2183332T3/es not_active Expired - Lifetime
- 1998-02-06 AU AU66206/98A patent/AU735313B2/en not_active Ceased
- 1998-02-06 KR KR1019997007297A patent/KR20000071030A/ko not_active Application Discontinuation
- 1998-02-06 ID IDW990812A patent/ID22533A/id unknown
- 1998-02-06 SK SK1071-99A patent/SK284646B6/sk unknown
- 1998-02-06 RU RU99119223/04A patent/RU2187506C2/ru not_active IP Right Cessation
- 1998-02-06 AT AT98908063T patent/ATE225776T1/de not_active IP Right Cessation
- 1998-02-06 EP EP98908063A patent/EP0964856B1/de not_active Expired - Lifetime
- 1998-02-06 CZ CZ0287599A patent/CZ297366B6/cs not_active IP Right Cessation
- 1998-02-06 CN CN98803959A patent/CN1085205C/zh not_active Expired - Fee Related
- 1998-02-06 JP JP53530398A patent/JP4327257B2/ja not_active Expired - Fee Related
- 1998-02-06 TR TR1999/01962T patent/TR199901962T2/xx unknown
- 1998-02-06 WO PCT/EP1998/000636 patent/WO1998035949A1/de active IP Right Grant
- 1998-02-12 ZA ZA981178A patent/ZA981178B/xx unknown
- 1998-02-13 AR ARP980100654A patent/AR010894A1/es not_active Application Discontinuation
-
1999
- 1999-08-12 NO NO19993901A patent/NO313289B1/no not_active IP Right Cessation
-
2003
- 2003-03-17 CY CY0300028A patent/CY2341B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0001138A2 (hu) | Benzodioxán vagy benzoxazin-gyűrűt tartalmazó aminosavak, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP9903716A2 (hu) | Alfa-integrin-gátló tirozinszármazékok | |
| HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
| HUP0004306A2 (hu) | Benzamidinszármazékok mint Xa-inhibitorok, azokat tartalmazó gyógyszerkészítmények, eljárás a vegyületek előállítására és alkalmazásuk | |
| EA200301094A1 (ru) | Аминопроизводные как ингибиторы протеазы | |
| HUP0101434A2 (hu) | Szulfonamidcsoportot tartalmazó indolszármazékok, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| MY117896A (en) | Quinazoline derivatives | |
| MY116542A (en) | New inhibitors of platelet aggregation. | |
| UY26276A1 (es) | 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164 | |
| HUP0002843A2 (hu) | Új béta-karbolin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| DK1473294T3 (da) | Substituerede1,3-oxathiolaner med antivirale egenskaber | |
| DK0791006T3 (da) | Polyanioniske benzylglylcosider som inhibitorer af proliferation af glatte muskelceller | |
| ATE283268T1 (de) | 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission | |
| HUP0100488A2 (hu) | Tieno-pirimidinek, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| EE02950B1 (et) | Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon | |
| HUP0003425A2 (hu) | 2-(4-Aril- vagy heteroaril-piperazin-ilmetil)-1H-indol-származékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| CA2250861A1 (en) | Cyclic adhesion inhibitors | |
| DE69512528D1 (de) | Glatten-muskelzellen-proliferation-inhibitoren | |
| HUP0102025A2 (hu) | Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE252590T1 (de) | Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon | |
| YU68502A (sh) | Piridazinil fenil hidrazoni korisni protiv kongestivnog srčanog udara | |
| HUP0203212A2 (hu) | Integrin inhibitorok, eljárás ezek előállítására, alkalmazásuk gyógyszerkészítmények előállítására és a készítmények | |
| ATE166872T1 (de) | Benzothiazol-derivate | |
| FR2687677B1 (fr) | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |